MIAX:NYSEMiami International Holdings, Inc. Analysis
Data as of 2026-05-19 - not real-time
$54.51
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Miami International Holdings (MIAX) is trading at $54.51, comfortably above its 20‑day SMA ($49.40) and well above the 50‑day ($44.10) and 200‑day ($42.49) averages, indicating strong bullish momentum. Technicals reinforce this view: the RSI sits at 73 (overbought but still supportive of upward pressure), the MACD line ($3.24) is above its signal ($2.65) and the histogram is positive, and the trend is flagged as bullish with increasing volume. However, the stock is near its resistance level of $57.14 and its DCF‑derived fair value of $38.84 suggests it is currently overvalued, with a downside potential of about 6%.
Fundamentally, MIAX posted 13% revenue growth, solid cash reserves ($596 M) and minimal debt ($22.7 M), delivering a 12.4% operating margin and an 8.6% profit margin. Analysts are optimistic, assigning a “Buy” rating and a Zacks Rank 2 upgrade, while the market sentiment is in “Extreme Greed” (Fear‑Greed Index 89). Yet the forward PE of 29.9 versus an industry average of 16.7 underscores a premium valuation. The combination of robust short‑term technicals, strong balance sheet, but elevated valuation and high short‑term volatility (≈31% 30‑day) frames a nuanced outlook.
Fundamentally, MIAX posted 13% revenue growth, solid cash reserves ($596 M) and minimal debt ($22.7 M), delivering a 12.4% operating margin and an 8.6% profit margin. Analysts are optimistic, assigning a “Buy” rating and a Zacks Rank 2 upgrade, while the market sentiment is in “Extreme Greed” (Fear‑Greed Index 89). Yet the forward PE of 29.9 versus an industry average of 16.7 underscores a premium valuation. The combination of robust short‑term technicals, strong balance sheet, but elevated valuation and high short‑term volatility (≈31% 30‑day) frames a nuanced outlook.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators (price above all SMAs, MACD bullish)
- RSI in overbought territory near resistance at $57.14
- Increasing volume supporting current trend
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong revenue growth (13%) and solid cash position
- Analyst upgrades and Zacks Rank 2 Buy
- Valuation premium (PE 42 vs industry 16) limiting upside
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- DCF fair value ($38.84) well below current price
- High forward PE (29.9) indicating limited long‑run upside
- Potential regulatory headwinds in capital‑markets segment
Key Metrics & Analysis
Financial Health
Revenue Growth13.00%
Profit Margin8.64%
P/E Ratio42.3
ROE16.83%
ROA7.03%
Debt/Equity2.13
P/B Ratio4.8
Op. Cash Flow$217.5M
Free Cash Flow$139.3M
Industry P/E16.7
Technical Analysis
TrendBullish
RSI73.0
Support$43.96
Resistance$57.14
MA 20$49.40
MA 50$44.10
MA 200$42.49
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25
Valuation
Fair Value$38.84
Target Price$51.20
Upside/Downside-6.07%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.70
Volatility30.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.